» Advanced search
Only first 10,000 results will be saved in the file.
No item is selected. Use checkboxes to select search results.
Displaying 851-875 of 1083 results.
 
{{ selectedCountPage }} items selected on this page, {{ selectedCountPage }} item selected on this page, {{ selectedCountTotal }} item in total {{ selectedCountTotal }} items in total
Study aim: Comparison between the efficacy of intravenous immunoglobulin and convalescent plasma in improving the condition of patients with COVID-19 Design: clinical trial with control group- randomized- parallel groups Settings and conduct: This study is a clinical trial with control group that will be
IRCTID: IRCT20200413047056N1
Study aim: the effectiveness of mindfulness-based stress reduction program on mental well-being, and quality of life of patients diagnosed with Covid-19 after discharge Design: a randomized clinical trial with a control group A simple random sampling method and a quadruple block will be used for random
IRCTID: IRCT20170218032635N3
  1. Designing and evaluation of Community empowerment and a web based healthy lifestyle intervention in women (Hamyaran)
  2. The effect of cognitive-behavioral intervention in reducing fear of COVID-19 symptoms, anxiety, depression, stress and improving the quality of life in people suffering from prolonged grief disorder due to the COVID-19
  3. Randomized controlled trial the effectiveness of Mindfulness-Based Stress Reduction program on Depression, Anxiety and Quality of life of hemodialysis patients
  4. Comparison of the quality of life of infertile women in two groups without receiving education and with presenting education based on mindfulness-based stress reduction program
  5. The effectiveness of online mindfulness training based on stress reduction (MBSR) on mental health and quality of work life of nurses fighting on the frontlines against COVID-19
  6. The Impact of Mindfulness-based Stress Reduction on Sleep Quality in Women Suffering from Multiple Sclerosis in Ahwaz
  7. Title: Effectiveness of Mindfulness-Based Stress Reduction (MBSR) Intervention on Psychological Symptoms, Quality of Life, Symptom Severity in Patients with Somatic Symptoms Disorder
  8. The effect of education on mindfulness-based stress coping skills on psychological distress in patients with Covid 19
  9. Comparison of the effectiveness of mindfulness based on stress reduction therapy and neurofeedback training on the clinical symptoms of individual with generalized anxiety disorder
  10. Comparison the effectiveness of group mindfulness-based stress reduction and group cognitive-behavioral stress management on biological markers and psychological symptoms in patients with essential hypertension
Study aim: Determining the effectiveness of the intervention to improve the level of resilience of nurses working in the COVID-19 wards Design: Clinical trial with control group, parallel design, single (...) degree in nursing • Work experience in the COVID-19 departments . A resilience scores lower than 75 on
IRCTID: IRCT20240222061081N1
inactivated Covid-19 vaccines and at least two months have passed since the last injection; Not being infected with Covid-19 by using a rapid corona test and evaluating clinical symptoms. Exclusion criteria: Having
IRCTID: IRCT20180103038199N13
  1. A double-blind, randomized, placebo-controlled Phase II/III Clinical trial to evaluate the safety and efficacy of COVID-19 inactivated vaccine (Shifa-Pharmed) in a population aged 18 to 75 years
  2. A double-blind, randomized, placebo-controlled Phase I Clinical trial to evaluate the safety and immunogenicity of COVID-19 inactivated vaccine (Shifa-Pharmed) in a healthy population aged 51-75 years
  3. A double-blinded, randomized, placebo-controlled Phase I Clinical trial to evaluate the safety and immunogenicity of COVID-19 inactivated vaccine (Shif-Pharmed) in a healthy population
  4. Phase 2 trial of safety and immunogenicity of 10 micro gram inactivated SARS-CoV-2 vaccine (FAKHRAVAC), two doses two weeks apart in adults aged 18-70 years: a randomized, double-blind, placebo-controlled, clinical trial
  5. Investigating the effect of Medical Beer on the fever of patients with COVID-19
  6. Comparison of the tolerability, safety, and immunogenicity of Shifa-Pharmed COVID-19 inactivated vaccine (CovIran) and Sinopharm vaccine in the healthy population aged 12 to 18 years: a double-blind, randomized, active-controlled, Phase I-II clinical trial.
  7. Immunogenicity and safety of pastocovac vaccine as a booster dose in comparison with sinopharm and pastocovac Plus boosters in Iranian adults aged 18 to 80 who received 2 doses of Sinopharm vaccine: a parallel group clinical trial
  8. Phase 1, safety, immunogenicity and dose finding for two strengths of 0.5 × 10^6 and 2.5 × 10^6 (TCID50) inactivated SARS-CoV-2 vaccine FAKHRAVAC (MIVAC) injected in two schedules of two doses, 2 and 3 weeks apart in healthy adults aged 18-55 years: a randomized, double blind, placebo controlled, clinical trial
  9. The effectiveness of dietary supplements containing antioxidant compounds on survival rate of patients with COVID-19
  10. A double-blind, randomized, placebo-controlled Phase II clinical trial to evaluate the immunogenicity and safety of covid-19 recombinant RBD protein vaccine (80 microgram) of Plasma Darman Sarve Sepid Co. in healthy population.
involvement with infection, mood state, sleep quality of hospitalized patients with COVID-19 in the (...) software Settings and conduct: 104 patients with covid-19 hospitalized in the non-special care department (...) with confirmed covid-19 in non-critical conditions and not hospitalized in the special care department
IRCTID: IRCT20220724055541N1
Study aim: Evaluation of the effectiveness of the new formulation of antioxidant dietary supplement on the outcome (duration of discharge and death) of COVID-19 patients Design: Clinical trial with (...) groups of patients (non-critical :) with Covid-19 disease (group receiving complementary therapy and
IRCTID: IRCT20160625028622N2
Positive COVID-19 PCR ; Women should not become pregnant for 30 days after the end of the study patients (...) levamisole; Use of drugs and antibiotics other than those used in the national COVID-19 treatment protocol
IRCTID: IRCT20201124049480N1
Study aim: Safety and immunogenicity evaluation of mRNA-based COVID-19 vaccine (COReNAPCIN (...) substances; Positive PCR test of COVID-19 or influenza or symptoms consistent with these diseases; History of COVID-19 diagnosis within the last 3 months; Vulnerable groups and foreigners Intervention groups
IRCTID: IRCT20230131057293N1
  1. Immunogenicity and Safety of intranasal Razi Cov Pars as a booster dose in adult population; randomised, double blind, placebo controlled clinical trial
  2. Efficacy, safety, and immunogenicity of Soberana recombinant vaccine (product of Finlay Institute) based on RBD protein subunit of Sars-Cov-2 in a 2-dose regimen with and without a booster dose: a double-blind, randomized, placebo-controlled phase III clinical trial in the Iranian population of 18-80 years
  3. A phase II, Randomized, Two-armed, Double-blind, Placebo controlled trial to evaluate efficacy and safety of an adjuvanted recombinant SARS-CoV-2 spike (S) protein subunit vaccine (SpikoGen®) produced by CinnaGen Co. (Two doses of 25µg with dosing interval of 21 days)
  4. Immunogenicity and safety of pastocovac vaccine as a booster dose in comparison with sinopharm and pastocovac Plus boosters in Iranian adults aged 18 to 80 who received 2 doses of Sinopharm vaccine: a parallel group clinical trial
  5. A Clinical trial to evaluate the immunogenicity and safety of Omicron-Based CovIran Barkat vaccine as a third injection dose in vaccinated population over 18 years of age
  6. A single armed, open label, clinical trial to evaluate the immunogenicity of SpikoGen® vaccine as booster dose (Spike protein, produced by CinnaGen company) in kidney transplant patients being fully vaccinated with Sinopharm vaccine
  7. A double-blind, randomized, placebo-controlled Phase II/III Clinical trial to evaluate the safety and efficacy of COVID-19 inactivated vaccine (Shifa-Pharmed) in a population aged 18 to 75 years
  8. Safety evaluation of a quadrivalent recombinant influenza vaccine (serotypes of 2021/2022) manufactured by Nivad Pharmed Salamat, open label, single arm, in volunteers aged ≥ 18 years.
  9. A randomized, two-armed, Placebo controlled (5:1), Double-blind, parallel clinical trial to compare the immunogenicity and safety of SpikoGen® vaccine (an adjuvanted recombinant spike (S) protein produced by CinnaGen Co.) as a booster dose
  10. Phase 2 trial of safety and immunogenicity of 10 micro gram inactivated SARS-CoV-2 vaccine (FAKHRAVAC), two doses two weeks apart in adults aged 18-70 years: a randomized, double-blind, placebo-controlled, clinical trial
of vaccination, Occurrence of COVID-19 disease 2 weeks after 2nd vaccine dose: SAEs, SUSARs, MAAEs (...) Study aim: Phase two of safety and immunogenicity of recombinant protein sub-unit Covid vaccine (...) ; Able to read and write; 18 - 70 years old; Negative RT-PCR tests for COVID, Negative S antibody titer
IRCTID: IRCT20201214049709N2
  1. Phase I, Safety and Immunogenicity of Razi SARS-CoV-2 recombinant Spike protein vaccine (Razi Cov Pars), in healthy adults aged 18-55 years; parallel 4 arms design (adjuvant only and three vaccine doses of 5, 10, and 20 µg/200µl); a Randomised, double blind, clinical trial
  2. Safety and Immunogenicity of Razi Cov-2 recombinant Spike protein vaccine (RAZI Cov Pars) in healthy children and adolescents aged 5-17 years; single group, open label study
  3. Comparison of immunogenicity and safety of Razi Cov Pars and Sinopharm booster doses in adults 18 years of age and older who have primarily vaccinated with Sinopharm: a ‎parallel ‎‏2‏‎ arms, ‎randomised, double blind clinical trial ‎
  4. Comparison of the safety and efficacy of Razi SARS-CoV-2 recombinant Spike protein (Razi Cov Pars) and Sinopharm vaccines in adults aged 18 and over, a phase III randomised, double blind, non-inferiority clinical trial
  5. Immunogenicity and Safety of intranasal Razi Cov Pars as a booster dose in adult population; randomised, double blind, placebo controlled clinical trial
  6. Phase 1, safety, immunogenicity and dose finding for two strengths of 0.5 × 10^6 and 2.5 × 10^6 (TCID50) inactivated SARS-CoV-2 vaccine FAKHRAVAC (MIVAC) injected in two schedules of two doses, 2 and 3 weeks apart in healthy adults aged 18-55 years: a randomized, double blind, placebo controlled, clinical trial
  7. Phase 2 trial of safety and immunogenicity of 10 micro gram inactivated SARS-CoV-2 vaccine (FAKHRAVAC), two doses two weeks apart in adults aged 18-70 years: a randomized, double-blind, placebo-controlled, clinical trial
  8. Comparison of safety and immunogenicity of FAKHRAVAC and Sinopharm booster doses for adults 18 years of age and older, fully vaccinated by Sinopharm: a ‎parallel ‎‏2‏‎ arms, ‎randomised, double blind clinical trial
  9. A randomized, double-blinded, placebo-controlled phase I clinical trial to evaluate the safety and immunogenicity of three dose regimens of COVID-19 RBD protein recombinant vaccine (AmitisGen; 80µg and 120µg) in a healthy population
  10. A double-blind, randomized, placebo-controlled Phase II clinical trial to evaluate the immunogenicity and safety of covid-19 recombinant RBD protein vaccine (80 microgram) of Plasma Darman Sarve Sepid Co. in healthy population.
treatment of COVID-19 Design: This study is a single-arm, uncontrolled, open-label clinical trial to evaluate the safety and efficacy of Remdesivir in COVID-19 patients. Settings and conduct: This (...) confirmed COVID-19 patients who are still progressing despite receiving standard treatment. Exclusion
IRCTID: IRCT20171122037571N2
  1. Randomzied trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care- Iranian SOLIDARITY multicentre trial
  2. Effects of Viroherb capsule and Fenugreek syrup derived from traditional Persian medicine on clinical and paraclinical outcomes and survival of patients with mild to moderate COVID-19 hospitalized in medical centers of Tehran University of Medical Sciences
  3. Evaluating the efficacy and safety of remdesivir in severe COVID-19 in hospitalized patients
  4. Evaluation of the safety and efficacy of tocilizumab (AryoGen ‎Pharmed Co., Iran) in patients with severe COVID-19‎
  5. The evaluation of safety and efficacy of Pembrolizumab (CinnaGen Co, Iran) in patients with COVID-19
  6. Efficacy and safety of colchicine on clinical improvement in patients with COVID-19: A randomized, double blind clinical trial
  7. Evaluation of safety and efficacy of hydroxychloroquine plus favipiravir drug regimen in comparison with hydroxychloroquine plus kaletra on the need for intensive care unit treatment in patients with COVID-19; a randomized, multicenter, parallel groups, open label study
  8. Safety and Immunogenicity of Razi Cov-2 recombinant Spike protein vaccine (RAZI Cov Pars) in healthy children and adolescents aged 5-17 years; single group, open label study
  9. Evaluating the Efficacy of Ivermectin in the Treatment of COVID-19 Patients
  10. Investigation of the safety and efficacy of Varasurf (ovine pulmonary surfactant, produced by Artiman Pharmed Alborz company) compared to Curosurf (porcine pulmonary surfactant produced by Chiesi company) in premature neonates with gestational ages between 28 and 34 weeks with respiratory distress syndrome (RDS)
/Inclusion and exclusion criteria: Admission for COVID-19 patients; ranging in age from 18 to 70 years old
IRCTID: IRCT20211020052819N1
  1. Evaluation of the effect of a natural product called 4 capsule plant based on Malus Domestica, Nigella Sativa, Peganum harmala, Terminalia chebula and vitamin C on clinical and laboratory, respiratory and prognostic symptoms of patients with Covid-19 virus
  2. Preparation of capsule form of hot water polysaccharide rich extract from Trametes versicolor and effect of it on blood factors in diabetic patients. A Double-Blind, Randomized Clinical Trial
  3. The effect of 8 weeks of intermittent exercise and Ganoderma mushroom consumption on the structure and function of the heart of women undergoing chemotherapy with breast cancer
  4. Study of the effectiveness of "SALIRAVIRA" as a natural product containing Licorice, Cone flower, Ginseng, Hyssop, Rhubarb and Rosemary extracts on the recovery of COVID-19 patients
  5. Investigating the effect of educational intervention based on the health belief model in the prevention and preparedness to deal with human monkeypox disease in the medical staff
  6. The Effect of a Persian Natural Medicine Product based on Tahini Oil on Clinical Signs in Suspected Patients with COVID-19
  7. Investigating the effect of sweet almond ,Oral product, as a supplement in patients with COVID 19
  8. The effect of L-carnitine supplementation on mortality and serum levels of C-reactive protein in obese patients with coronavirus (nCov-2019) with acute respiratory failure admitted to intensive care unit
  9. Evaluating the effect of Cyclosporine in prognosis and clinical improvement in patients with COVID-19: A Randomized Clinical Trial Study
  10. Evaluation of the effect of Ganoderm lucidum (with usual diabetes medications) on blood glucose control in type 2 diabetic patients: A placebo-controlled double-blind clinical trial
phones and at the end of surgery through the link sent Receive wound care and Covid-19 awareness. The (...) status. At the end of the surgery, the wound care and Covid-19 awareness will be sent to the mobile
IRCTID: IRCT20210301050536N1
Study aim: Determining the combined effect of deep breathing and prone position on common respiratory symptoms in patients with COVID-19 Design: Clinical trial without control group, with parallel, randomized groups, 96 patients Settings and conduct: Approval of the ethics committee. Complete the informed
IRCTID: IRCT20210423051056N1
-test Having Covid-19 during the study Death of participant due to a specific illness or accident
IRCTID: IRCT20191026045251N2
caused by Covid 19 Design: Single-blind, randomized clinical trial without a control group, with (...) due to COVID-19 in the last 6 months and are eligible to be included and have a file in one of the (...) individuals who have experienced the death of a first-degree relative due to COVID 19 during the last six
IRCTID: IRCT20201119049445N1
  1. Effect of a Compassion Focused Program on Grief Exprience of Caregivers of Dementia Persons.
  2. Comparison of the efficacy of three versus five sessions of grief counseling on general health, quality of life and intensity of grief in family members of the COVID-19 victims: A multi-center randomized controlled trial
  3. Developing a Model of Integrative Act Matrix & comparison of its effectiveness with Acceptance and Commitment Therapy Focused on Self –Compassion & Cognitive-behavioral therapy based on Hofmann's model on Social Anxiety Disorder (Single-subject study with multiple baseline)
  4. The Effectiveness of Self-Compassion-Focused Therapy on Cognitive Vulnerability to Depression in Students of Bu-Ali Sina University
  5. Effectiveness of compassion-focused therapy on psychological symptoms of women with recurrent spontaneous abortion
  6. The Comparison of the Effectiveness of Pharmacotherapy and online Compassion-Based Therapy in Reducing the Severity of Post Traumatic Symptoms, Increasing Post-Traumatic Growth, Improving Quality of life, and Studying Changes in Hippocampal and Amygdala Volume in Improved Patients with Coronavirus
  7. Comparison of the effect of grief counseling based on Compassion-Focused Therapy and counseling based on Acceptance and Commitment Therapy on self-compassion and self-efficacy of women who experienced fetal loss: a randomized controlled trial.
  8. A qualitative study of psychological components in Prolonged grief disorder by suicide, and The Efficacy of Compassion-focused group therapy on The recovery of this disorder
  9. The comparison effect of medical and psychological interventions on women's psychiatric disorders after miscarriage
  10. The efficacy of Trauma-focused cognitive behavioral therapy on reducing trauma symptoms and improving cognitive function in children with posttraumatic stress symptoms
Study aim: The effect of pirfenidone on prevention and treatment of pulmonary fibrosis and acute respiratory distress syndrome caused by COVID-19 Design: Randomized clinical trial, with parallel (...) . Participants/Inclusion and exclusion criteria: Inclusion criteria o Confirmed cases of COVID-19 who are 18
IRCTID: IRCT20200314046764N1
alleviate COVID-19 patients symptoms Design: Clinical trial with control group with parallel groups (...) . Settings and conduct: Available standard treatment (according to the latest protocol of the Covid-19 (...) positive PCR test COVID-19 With inpatient clinical criteria (T>38°C or severe cough or shortness of breath
IRCTID: IRCT20201111049349N1
Study aim: Comparing safety and efficacy of Favipiravir and Kaletra in COVID-19 Design: Randomized (...) criteria: Inclusion criteria: Diagnosis of COVID-19 based on either ground glass appearance in chest CT scan or positive RT-PCR test for COVID-19; Requiring hospitalization; Patient's age between 16 and 100
IRCTID: IRCT20200318046812N1
  1. Safety and efficacy of “Hydroxychloroquine + Azithromycin + Naproxen + Prednisolone” and “Hydroxychloroquine + Azithromycin + Naproxen” regimens in comparison with “Hydroxychloroquine + kaletra” on the need for intensive care unit treatment in patients with COVID-19; a randomized, multicenter, parallel groups, open label study
  2. Evaluation of safety and efficacy of hydroxychloroquine plus favipiravir drug regimen in comparison with hydroxychloroquine plus kaletra in hospitalized patients with COVID-19
  3. Evaluation of safety and effectiveness of favipiravir in comparison with Tenofovir Alafenamid in hospitalized patients with COVID-19
  4. Evaluation of the efficiency and safety of favipiravir + hydroxychloroquine drug regimen in comparison with hydroxychloroquine in hospitalized patients with covid-19
  5. Evaluation the efficacy and safety of Favipiravir made by Shahid Beheshti University of Medical Sciences in comparison with Lopinavir-ritonavir in COVID-19 patients
  6. Evaluation of the effect of herbal medicine containing Saatar, Hofarigon and Fennel on reduction of pulmonary complications of COVID-19 in patients: a clinical trial
  7. Evaluation of treatment strategy Included : hydroxychloroquine ,naproxen and oseltamivir for outpatient patients with Covid 19
  8. Safety and Effectiveness of azithromycin in Patients with COVID-19 Referred to zeiaeian Hospital : A clinical trial study
  9. Effect of Intravenous immunoglobulin (IVIG) versus Kaletra (lopinavir and ritonavir) tablets in patients with acute respiratory infection (COVID-19): A clinical trial studies
  10. The effect of plasma therapy in the treatment of patients with COVID-19 infection. Randomized, open-label
Study aim: The aim of this study was to develop an analytical metacognitive therapy protocol using intervention mapping and its effect on my ability and reduce anxiety and depression of nurses involved with Covid-19 patients. Design: In the first stage, the intervention protocol is developed using cartography
IRCTID: IRCT20180705040356N1
problem inventory and covid-19 anxiety at the beginning of the intervention, 4 weeks after the beginning (...) criteria: inclusion criteria: aged 19-45 years, more than five years of education, based on Beck's
IRCTID: IRCT20110228005931N9
  1. Comparison of effect of compute-based versus face- to-face cognitive behavioral therapy for improvement of symptoms of adjustment disorders in infertile women
  2. Comparison of efficacy of internet- based cognitive behavior therapy alone versus combination CBT with well-being therapy for improvement of depressive symptoms of pregnant women
  3. Comparing the effectiveness of cognitive-behavioral therapy with combined cognitive-behavioral therapy (face-to-face + web-based application) university students' maladaptive perfectionism
  4. The Effectiveness of Internet-Based Psychological Intervention in patients with symptoms of depression and anxiety
  5. The effect of cognitive group therapy on improvement internet addiction symptoms, peomotion of quality of life and mental health in students 19-30 years
  6. Investigating the effect of Cognitive behavioral therapy and Neurofeedback in pregnant women on perinatal Concern, Depression, Anxiety, Stress and postpartum Depression
  7. The efficacy of cognitive-behavioral therapy based on Rumination on depression, anxiety and hostility in patients undergoing cardiac rehabilitation
  8. Comparison of the effectiveness of cognitive-behavioral therapy and motivational interviewing on the symptoms of anxiety sensitivity, depression and self-esteem in divorced women covered by comprehensive health service centers in Khomein city.
  9. The efficacy of acceptance and commitment therapy on emotional, cognitive, physiological functions and quality of life in infertile women who undergoing in vitro fertilization
  10. The effectiveness of internet-based emotion-focused cognitive behavior therapy (iECBT) with and without spouse participation on psychological distress and stress in pregnant women with anxiety disorders
Study aim: The effect of family-centered empowerment model on stress, anxiety and family satisfaction in patients with Covid-19 Design: Clinical trial with control group, with parallel groups,Two (...) will be performed on the families of patients with Quaid 19 disease referred to the 9th Di Torbat
IRCTID: IRCT20180429039463N2
Study aim: The evaluation of efficacy and safety of Tocilizumab (AryoGen Pharmed Co.) in patients with severe ‎COVID-19.‎ Design: This is a phase III, open-label, and single-arm study with the sample (...) cities of Iran) clinical trial will be conducted in patients with COVID-19 with a follow-up duration of
IRCTID: IRCT20150303021315N17
  1. A Phase III, randomized, two-armed, double-blind (patient and assessor blinded), parallel active controlled non-Inferiority clinical trial to evaluate the efficacy and safety of bevacizumab(AryoGen®) plus FOLFIRI-3 in comparison with bevacizumab (Avastin®) plus FOLFIRI-3 as a first line therapy in patients with metastatic colorectal cancer (mCRC)
  2. Efficacy of Tocilizumab in Hospitalized Patients with COVID-19: An open-label placebo-controlled clinical study
  3. Evaluation of Efficacy and Safety of Inhaled Tocilizumab in Comparison with Intravenous Tocilizumab in Hospitalized Patients with COVID-19
  4. Multicenter, Open-Label, Phase IV Study to Evaluate the Safety,Tolerability, and Efficacy of Tocilizumab in Patients with Active Rheumatoid arthritis on background non-biologic DMARDs who have an inadequate response to current non-biologic DMARD and/or Anti- TNF therapy
  5. The evaluation of safety and efficacy of Pembrolizumab (CinnaGen Co, Iran) in patients with COVID-19
  6. Evaluation of safety and effectiveness of favipiravir in comparison with Tenofovir Alafenamid in hospitalized patients with COVID-19
  7. A randomized, two-armed, double-blind, single-dose, crossover, two sequence, active-controlled, multi-center, bioequivalence clinical trial to compare PK parameters and safety of Factor VIII, recombinant human with Fc fusion (rFVIII-Fc) (Coageight, produced by AryoGen Pharmed Company (versus rFVIII-Fc (Elocta®, produced by Sobi Company) in previously treated patients with severe hemophilia A
  8. A phase 3, randomized, multicenter, double-blind, two-armed, parallel, active-controlled, equivalency clinical trial to compare efficacy and safety of Temziva (Tocilizumab produced by AryoGen Pharmed) versus Actemra® (Tocilizumab produced by Genentech-Roche co.) in patients with active moderate to severe rheumatoid arthritis
  9. Evaluation of the efficacy and safety of Co-trimoxazole in patients with COVID-19: A randomized open-label clinical trial
  10. Evaluating the efficacy and safety of Adalimumab in patients with COVID-19
performance, and quality of life in people with post-COVID-19 syndrome. Design: This study will be a blinded (...) fatigue and shortness of breath, after a period of infection with COVID-19 and at least 3 months have
IRCTID: IRCT20231207060287N1
  1. The Effect of Pulmonary Rehabilitation on Depression, Anxiety, Fatigue and Quality of Life in COVID-19 Patients with one-month Follow-up
  2. Effects of 8 weeks of combined aerobic and resistive exercise on fat percentage, quality of life and fatigue in patients with pulmonary sarcoidosis
  3. Effect of the breathing exercises on quality of life and symptoms of shortness of breath and fatigue in patients with Covid 19
  4. Evaluation of the effectiveness of pulmonary rehabilitation and exercise therapy in reducing the length of hospital stay of patients with Covid-19
  5. Study of the effectiveness of "SALIRAVIRA" as a natural product containing Licorice, Cone flower, Ginseng, Hyssop, Rhubarb and Rosemary extracts on the recovery of COVID-19 patients
  6. The immediate effectiveness of a single session of Whole-Body Vibration in improving the balance in patients with Type 2 diabetic neuropathy
  7. The effect of NOSCOVID on pulmonary & other clinical manifestations of COVID-19 patients
  8. Evaluation of the effectiveness of eight weeks of pulmonary rehabilitation on cardiopulmonary parameters and quality of life in patients with scleroderma with pulmonary involvement
  9. The effect of cognitive-behavioral intervention in reducing fear of COVID-19 symptoms, anxiety, depression, stress and improving the quality of life in people suffering from prolonged grief disorder due to the COVID-19
  10. The effect of cognitive practice with and without whole body vibration on balance indicators in type 2 diabetic patients with peripheral neuropathy
Study aim: The effect of spirulina platensis supplementation on disease severity and mortality in patients with coronavirus. Design: This clinical trial has parallel intervention and control group, open-label, randomized, multicenter, phase 3 on 240 patients. Random Allocation Software was used for randomization. Settings and conduct: The present study is an open-label clinical trial. The target population is patients hospitalized in the coronavirus ward of Ziaeian Hospital and Baharloo Hospital. Participants/Inclusion and exclusion criteria: Patients with coronavirus. Inclusion criteria 1- Male and female patients, age ≥18. 2- The patient is stable in condition and does not need resuscitation. 3- Signed informed consent form. 4- Definitive/clinical diagnosis of coronavirus. ... Exclusion criteria 1- Pregnancy or lactation. 2- Any history of drug allergy. 3- Active, clinically significant chronic illness or human immunodeficiency virus disease. 4- Significant organ dysfunctions such as renal failure, liver dysfunction, CHF, or serious and unstable cardiac condition. ... Intervention groups: Based on the entry criteria, patients who are eligible to enter the study are randomly divided into two intervention and control groups using the block randomization method. After obtaining consent from the patients, the intervention group will receive 15/2 g spirulina platensis algae powder daily. Main outcome variables: Reducing the severity of the disease and its mortality.
IRCTID: IRCT20210216050373N1
  1. A clinical trial to compare the effectiveness of the Spirulina platensis algae (Arthrospira, blue-green algae) and N-acetyl cysteine with standard treatment in patients with COVID-19 infection
  2. Effect of spirulina platensis supplementation on quality of life, severity of disease and serum total antioxidant capacity (TAC), manoldialdehyde (MDA) and zonulin in Irritable bowel syndrome patients (IBS)
  3. Clinical evaluation of the efficacy of purified bioactive peptides from Spirulina Platensis algae on the healing of wounds after periodontal flap surgery (double-blinded randomized clinical trial)
  4. Investigating effect of Spirulina (Arthrospira platensis) dietary supplementation on COVID-19 disease outcomes in patients admitted to Intensive Care Units of hospitals: phase 2 clinical trial
  5. The Effect of Spirulina Platensis on fasting blood Glucose, Glycosylated Hemoglobin (HbA1c) and Lipid Profile in Type 2 diabetic Patients in Mashhad
  6. The effects of Spirulina Platensis on anemia status in patients with ulcerative colitis
  7. Survey and Comparison of the effect of fortified yogurt enriched with fermented and non-fermented Spirulina Platensis extract on reducing oxidative stress in patients with type 2 diabetes mellitus
  8. Effect of Spirulina supplement (Arthrospira platensis) on disease activity indices, quality of life, mood, fatigue, serum antioxidant status and serum pentraxin 3 levels in patients with ulcerative colitis
  9. Evaluation of oxidative stress biomarkers in type 2 diabetic patients consuming fermented and non-fermented spirulina platensis
  10. The Effect of Spirulina Platensis Algae Supplementation on Serum Concentration Macrophage Inhibitory Cytokine (MIC-1), Superoxide Dismutase (SOD) and Glutathione Peroxidase (GPX) and Appetite in Obese Individuals
Study aim: Comparison of the therapeutic effect of vitamin A and olfactory rehabilitation in improving anosmia, hypovasemia in patients with COVID-19 disease Design: This study is a controlled (...) Baqiyatallah Hospital. In this study, 90 positive Covid patients with anosmia and hyposemia for more than 2
IRCTID: IRCT20210205050247N1
Loading...